HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

摘要: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Background Patients end-stage renal disease (ESRD) suffer from markedly higher rates of cardiovascular than the general population. Although therapy 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) ("statins") has been demonstrated to reduce patients without ESRD, only 10% on dialysis treated these medications by day 60 ESRD. We determined whether use statins is a reduction cardiovascular-specific death and total Methods Data were analyzed U.S. Renal System Dialysis Morbidity Mortality Wave-2 study, cohort randomly selected who initiating 1996. Information about as well other baseline characteristics was abstracted patients' records personnel. Cox proportional hazards models developed determine association between at subsequent risk mortality, adjustment for known factors. Results Follow-up data available 3716 through July 1998. At baseline, 362 (9.7%) using statins. These had rate 143/1000 person-years, compared 202/1000 person-years not Statin independently [relative (RR) = 0.68, 95% confidence interval (CI) 0.54, 0.87] (RR 0.64, CI=0.45, 0.91). In contrast, fibrates 1.29). Conclusions dialysis.